Dextromethorphan/bupropion

Dextromethorphan/bupropion
	Dextromethorphan
	Bupropion
Combination of
Dextromethorphan	NMDA receptor antagonist, σ1 receptor agonist, serotonin-norepinephrine reuptake inhibitor, nicotinic acetylcholine receptor negative allosteric modulator, and other actions
Bupropion	Norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator
Clinical data
Trade names	Auvelity
Other names	DXM/BUP; AXS-05
License data	US DailyMed: Dextromethorphan and bupropion;
Routes of; administration	By mouth
ATC code	N06AX62 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	2360540-77-6;
KEGG	D12493;

Dextromethorphan/bupropion (DXM/BUP), sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD). Its active components are dextromethorphan (DXM) and bupropion. Patients who stayed on the medication had an average of 11% greater reduction in depressive symptoms than placebo in an FDA approval trial. It is taken as a tablet by mouth.

Side effects of dextromethorphan/bupropion include dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis, among others. The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown.

Dextromethorphan/bupropion was developed by Axsome Therapeutics and was approved for the treatment of major depressive disorder in the United States in August 2022.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.